Kura Oncology missed GAAP revenue estimates in Q2 2025. Ziftomenib advanced to FDA Priority Review, hitting key clinical and regulatory milestones, with no product sales yet. Research and ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ: ASND) shares gained 2.9% after the biopharmaceutical company reported a narrower-than-expected second-quarter loss and revenue that exceeded analyst estimates ...

QNRX READ THE FULL QNRX RESEARCH REPORT FDA clears initiation of 2nd NS pivotal whole body clinical study for QRX003, CL-QRX003-002 Quoin Pharmaceuticals (NASDAQ:QNRX) reported 2Q25 results today and ...

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 ...

US FDA grants fast track designation to Dizal’s Birelentinib to treat relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma: Shanghai, China Thursday, ...

The issue with placing it on the floodplain is that it reduces the available area for floodwaters to spread out and slow down,” one neighbor said.

VRX Silica has moved a step closer to production at Arrowsmith North, hitting a 12-month high intra-day Friday after clearing ...

Wessex, which missed out on the devolution priority programme, has announced a number steps locally to lay the groundwork for ...

I tested Google's Gemini AI for two months to see if it could boost my output and transform my daily routine. My boss and my ...

MSU is pausing a 'transition of psychiatric services for students,' apparently in response to pushback to layoffs of staff ...